Alkermes to Merge with Elan and Become Alkermes plc

Alkermes and Elan to be combined under a new holding company to be incorporated in Ireland by Q3 2011
Alkermes plc is expected to have annual revenues of more than $450 million annually, and increased resources to invest in a growing pipeline of proprietary drugs. The merger of the two companies also means new drug development capabilities that leverage proprietary technologies and innovative medical chemistries from both companies. Novel technologies include Elan’s NanoCrystal® technology for poorly water soluble drug compounds, and technologies for oral controlled release drugs. Alkermes brings injectable drug technologies and
advanced manufacturing facilities in the US and Ireland.

↑ Back to TechConnect News™

Annual Meeting

TechConnect World 2015
National Harbor, MD, June 29 thru July 1, 2020